Introduction
============

Acute or chronic compressive radiculopathies and/or myelopathies are associated with a wide range of transitory or permanent neurological disturbances \[[@B1],[@B2]\]. Less commonly, as a result of these traumatic events, the development and progression of pain, loss of power and muscle wasting can be observed over time. These neurological features are more typical of amyotrophic neuralgias, neuromuscular disorders better known as idiopathic or genetically-induced conditions \[[@B3]\]. Different modalities of neurotraumas have also been linked to the development of either localised muscle wasting (focal amyotrophy), or to the development of a more widespread form of muscle weakness and wasting which become clinically indistinguishable from motor neuron disease (MND), an irreversible and generally fatal neurodegenerative disorder associated with a survival of approximately 3 to 5 years from disease onset and to the loss of motor cells in the cortex, brain stem and spinal cord \[[@B4]\]. Case studies have indicated how amyotrophic lateral sclerosis (ALS), a clinical form of MND, may have a higher occurrence in individuals exposed to hard physical contact, including mechanical traumas to the head, neck or back \[[@B5]-[@B18]\]. The potential role of trauma in engendering ALS also emerges in association with other stressors, like bone fractures and surgical intervention \[[@B19],[@B20]\].

From a molecular perspective, the clinical observations reported above suggest that a neurotrauma may mobilise molecular processes leading to a progressive neurodegenerative disorder normally occurring as an idiopathic or genetically-induced condition. The development of a progressive neurodegenerative disorder following spinal cord injury (SCI) may be facilitated by a genetic trait which renders certain individuals more vulnerable to the pre-existence of a sub-clinical degenerative process in the affected tissue, which is more likely to be present with aging and to be made worse and/or precipitated by neurotrauma. The recognition of molecular factors determining the hitherto unforeseen consequences of neurotrauma constitute an important step towards the understanding of neurodegeneration and towards the development of novel treatment strategies and biomarkers. This paper will review the molecular response to spinal trauma and its temporal unravelling, as well as those states known to modulate spinal cord tissue vulnerability to trauma.

Spinal cord injury: early and late *injury genes*and tissue regeneration
------------------------------------------------------------------------

Different molecules and their spatio-temporal activation in the injured tissue may have diverging effects on total cell loss and on tissue regeneration. As such, they determine the outcome of SCI. Mechanical injuries cause necrosis of those neurons directly affected by the force of impact (primary injury phase). A secondary injury phase is characterised by a protracted neuronal loss driven by changes in oxygen, glucose, neuroactive lipids and eicosanoids homeostasis, by the release of free radicals and biogenic amines, endogenous opioids and excitatory amino acids \[[@B21]-[@B27]\]. The use of large-scale spinal cord transcriptional analysis in well-established animal models of SCI has shown the rapid differential regulation of a number of genes, here referred to as early *injury genes*(within a few hours from injury), and the slower response of others termed as late *injury genes*(more than 48 hours from injury). Expression profiling of injured spinal cord tissue is a powerful method for unearthing the molecular consequences of trauma, particularly if gene expression changes are considered in light of the associated functional and histopathological alterations. In Figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"} we have reported the main molecular responses which have been described in the rat spinal cord following injury, according to recent pathway analyses of gene expression studies and to other relevant transcriptomic studies of SCI \[[@B28],[@B29]\]. Within each molecular pathway, we have selected some of the most representative differentially regulated genes with a very early and a late activation (genes activated in the first few hours from injury and after 48 hours respectively). The figures display the levels of transcriptional regulation and the position of the reported gene expression change with respect to the epicentre of injury, along with the functional role and the neuropathological changes which have been associated with the differential regulation of each gene.

![**Differentially regulated genes that become activated or inhibited within the first few hours from injury, reported as early *injury genes***. Examples of molecular responses (pathways) identified in normal rodent spinal cord after mechanical injury, according to the pathway analysis of recent transcriptomic studies of SCI \[[@B28],[@B29]\]. We report information regarding the functional and neuropathological effects that each reported gene may have, based on an overview of published data. The nature of the differential regulation and the location of the transcriptional change with regard to the epicenter of injury are also reported. Blue color indicates an increase in gene expression. Red color indicates a decrease in gene expression. References: 1; Aimone et al., \'04, 2; Bareyre et al., \'02, 3; Carmel et al., \'01, 4; Di Giovanni et al., \'03, 5; Malaspina et al., \'08, 6; Nesic et al., \'02; 7; Pan et al., \'02; 8; Resnick et al., \'04; 9; Schmitt et al., \'06, 10; Song et al., \'01.](1750-1326-7-6-1){#F1}

![**Differentially regulated genes that appear to have a delayed response which become activated or inhibited more than 2 days from the trauma, reported as late *injury genes***. Examples of molecular responses (pathways) identified in normal rodent spinal cord after mechanical injury, according to the pathway analysis of recent transcriptomic studies of SCI \[[@B28],[@B29]\]. We report information regarding the functional and neuropathological effects that each reported gene may have, based on an overview of published data. The nature of the differential regulation and the location of the transcriptional change with regard to the epicenter of injury are also reported. Blue color indicates an increase in gene expression. Red color indicates a decrease in gene expression. References: 2; Bareyre et al., \'02, 11; Fan et al., \'01, 12; Jokic et al., \'10.](1750-1326-7-6-2){#F2}

A number of molecular pathways become activated in an early post-SCI phase (less than 48 hours from SCI; Figure [1](#F1){ref-type="fig"}) \[[@B29]-[@B39]\]. This early response, mostly reported at the epicentre of injury, encompasses biological signals and early *injury genes*which have opposite effects on cell survival. Whilst apoptotic and pro-inflammatory responses are likely to be detrimental to cell survival other more protracted growth signals facilitate tissue repair. Among the latter, metallothioneins promote angiogenesis and neuronal re-growth \[[@B30],[@B37],[@B38]\]. Cytoskeletal proteins impact variably on tissue survival. Loss of neurofilaments like the microtubule-associated proteins (*Map2*) for example, prevents neurotoxic protein aggregates disrupting axonal transport, whilst vimentin up-regulation reduces the protracted release from macrophages of toxic reactive oxygen species (ROS) \[[@B37],[@B38],[@B40],[@B41]\]. A reduction in Ca2+ ATPase activity in the injured tissue causes a neurotoxic increase in intracellular calcium and up-regulation of genes modulating cell cycle mostly resulting in neuronal death. In contrast, down-regulation of genes involved in neurotransmission via regulation of sodium and potassium channels as well as AMPA receptors exert an anti-apoptotic effect \[[@B30]-[@B32],[@B39],[@B42]-[@B48]\]. The change of neurons and axons membrane excitability has been associated to neuronal degeneration in animal models and in neurophysiological studies conducted on patients with ALS \[[@B49],[@B50]\]. The predominant down-regulation of these signals may thus be seen to play a part in the cell-survival drive.

Delayed molecular responses, mostly identified distally from the injury epicentre, involve the differential regulation of late *injury genes*which modulate apoptosis, growth, neurotransmission, the homeostasis of the extracellular matrix and of cell metabolism (Figure [2](#F2){ref-type="fig"}) \[[@B28],[@B31],[@B34]\]. Some of these late responses can have an effect on lipid metabolism. For example, the differential regulation of glycerol-3-phosphate dehydrogenase *(Gpd1)*, a mitochondrial enzyme bridging carbohydrate and lipid metabolism, reduces ROS generation whilst the dioxygenase 12-lipoxygenase *(Alox12)*may work along the same lines, incorporating oxygen into specific positions of polyunsaturated fatty acids \[[@B31],[@B51],[@B52]\]. The down-regulation of anti-apoptotic genes such as *cat*, *Bag1*and *Bcl2*can exert an increase in neuronal cell death \[[@B53]\]. As already mentioned, the late activation of key modulators of membrane excitability also reported to become over-expressed in ALS, such as the hyperpolarization-activated cyclic nucleotide-gated cation channel *(Hcn)*, is likely to impair the functional recovery by enhancement of axonal excitability \[[@B54]\] Similarly to growth factors, heat shock proteins exert a neurorestorative effect for neurons, glial and muscle cells, both as a rapid and as a delayed response \[[@B32],[@B35],[@B37]-[@B39],[@B55]\].

Increased vulnerability to spinal trauma: what does it hide?
------------------------------------------------------------

The degree of tissue destruction and the residual neurological disability following SCI depend primarily on the nature of the mechanical stress (e.g. penetrating injuries versus compressive and/or traction type of impact) \[[@B29]-[@B39]\], on the different spatial distributions and temporal activations that different neurorestorative and neurodestructive molecular signals may have, in line with those reported in animal models of SCI (Figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}). Certain states modify the response to SCI, including a) the pre-existence of a subclinical neurodegenerative process, a situation that becomes more likely with aging, and b) the presence of a specific genetic trait which increases the vulnerability to trauma.

### Neurodegeneration and the effects of trauma

Acute and chronic traumatic encephalopathies in collision sports have been linked to the deposition of TAR DNA-binding protein 43 (*Tardbp)*in the brain, a hallmark of ALS pathology, in individuals who will later be affected by a neuromuscular disorder indistinguishable from ALS \[[@B13]\]. Hence, neurotrauma could initiate an ALS-like neuropathology or worsen a pre-existing sub-clinical ALS state. This concept has been investigated using pre-symptomatic rodent models of ALS, engineered using the mutant human superoxide dismutase 1 *(SOD1)*gene which is found in up to 10% of familial cases of ALS \[[@B28],[@B56],[@B57]\]. Both pre-symptomatic *SOD1* mutated rats and mice showed a poor post-injury locomotor recovery, compared to wild type littermates, following mild compression SCI and sciatic nerve injury respectively \[[@B28],[@B56]\]. In the post-injury phase, the transgenic rat cord displayed a more robust activation of several pro-apoptotic genes, cytochrome-C release, a high level of expression of neurofilaments and an early activation of a wide range of inflammatory signals \[[@B28]\]. It has also been possible to identify a significant activation of molecules involved in lipid metabolism, in isoprenoid biosynthesis and in the proteasome ubiquination system, along with a late up-regulation of lysosomal cysteine proteases and of genes involved in neurotransmission. A more subdued surge of growth-promoting signals at the epicenter of injury is another characteristic of the injured transgenic *SOD1*spinal cord \[[@B28],[@B58]-[@B61]\]. Whilst the post-injury transgenic spinal cord displays an altered transcriptional profile compared to wild type tissue, there are no overt histopathological differences between these tissues with regard to the extension of myelin destruction, motor cell loss and the inflammatory infiltrates caudal to the epicenter of injury \[[@B28]\]. This observation illustrates how SCI in pre-symptomatic animals carrying a *SOD1*gene mutation may not necessarily cause more structural changes compared to wild type animals, although the trauma may be disruptive enough at a molecular level to instigate functional disruption.

### Aging and SCI

Elderly patients have a 5 to 8-fold higher mortality rate following SCI compared to younger patients \[[@B62]-[@B66]\]. The vulnerability to SCI in the elderly may be linked to a process of senescence of the brain, involving beta amyloid deposition in neurons and microglia \[[@B67]-[@B69]\]. Aging is also one of the most important risk factors for the development of most neurodegenerative disorders, which manifest clinically after the progressive accumulation of microscopic tissue alterations in the CNS has overcome a certain threshold. Acute or chronic traumatisms may accelerate this process of abnormal protein deposition, leading to the premature surfacing of neurodegenerative conditions. Trauma to the neuroaxis can also enhance the level of protein aggregation, a process that causes the appearance of the histological hallmarks of idiopathic and genetically induced neurodegenerative disorders \[[@B40],[@B70],[@B71]\]. The spectrum of protein aggregates observed in neurodegenerative disorders whose expression could be conditioned by trauma includes beta amyloid and phosphorylated tau proteins normally observed within neurofibrillary tangles in Alzheimer\'s disease \[[@B72]\], alpha-synuclein within Lewy bodies found in Parkinson\'s disease \[[@B73]\], neurofilaments in bunina and spheroids bodies typical of ALS neuropathology and prion protein in Prion disease \[[@B71]\]. Trauma may further impair axonal transport and the functioning of the proteasome system, two molecular functions at the origin of the formation of most toxic protein aggregates.

### Genes modifying the molecular response to trauma

Recent experimental data show how a number of genes may act as modifiers of animals and humans response to SCI, thus collectively or independently increasing one\'s susceptibility to injury (Table [1](#T1){ref-type="table"} and Figure [3](#F3){ref-type="fig"}). Allelic variants of these genes or mutations causing loss or gain of function condition the unraveling of various molecular cascades which are key components of the response to injury (Figure [3](#F3){ref-type="fig"}). An altered protein cleavage, one of the main driving forces behind protein aggregation in neurodegenerative disorders, can be further enhanced by trauma in the presence of specific Apolipoprotein E (Apoe) and beta amyloid precursor protein (App) variants. The *ApoE4*allele has been unanimously linked to an increased risk of late onset Alzheimer\'s disease and to the development of other neurodegenerative disorders with professional boxing \[[@B74]\]. Loss of Apoe reduces recovery following neurotrauma or ischemic insults, as shown in *Apoe*-deficient mice whereas carriers of the *ApoE4*allele have also a 4 to 6-fold increased risk of developing cervical spondylotic myelopathy (CSM) in a situation of chronic spinal cord compression \[[@B2],[@B75]\]. *Apoe*fragments produced by the trauma-induced proteolytic cleavage of this protein may disrupt the cell\'s cytoskeleton by phosphorylation of tau and promote neurofibrillary tangles which ultimately cause neuronal death \[[@B76],[@B77]\]. Hence the detrimental effect of the *ApoE4*allele in neurodegeneration may be partly due to its higher susceptibility to proteolytic cleavage compared to E2 or E3 isoforms \[[@B78]\]. Similarly, a derangement of proteolysis may explain the increased level of deposition of beta amyloid following trauma, as demonstrated neuropathologically in humans and transgenic mice (Tg2576) expressing mutant human beta amyloid precursor protein \[[@B52],[@B72],[@B79]\].

###### 

Gene modifiers of the response to spinal cord injury and/or to neurotrauma.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene variant   Experimental paradigm                         Gene function                                                                 Neuropathology                          References
  -------------- --------------------------------------------- ----------------------------------------------------------------------------- --------------------------------------- ---------------------------
  ApoE           Human and ApoE -/- animal models              Lipid transport                                                               Neurofibrillary tangles                 Jordan et al., 1997\
                                                                                                                                                                                     Saunders et al., 1993\
                                                                                                                                                                                     Setzer et al., 2008

                                                                                                                                                                                     

  ABCD1          Human carriers                                Transport and metabolise very long-chain fatty acids                          Axonal demylination                     Berger & Gartner, 2006\
                                                                                                                                                                                     Fatemi et al., 2003\
                                                                                                                                                                                     Raymond et al., 2010

                                                                                                                                                                                     

  Bach1          Bach -/- mice                                 Pro-oxidant; (transcriptional repressor of heme oxygenase-1)                  Cellular death                          Kanno et al., 2009\
                                                                                                                                                                                     Yamada et al., 2008

                                                                                                                                                                                     

  SOD1           Animal models                                 Oxidative stress, apoptosis, inflammation, neurofilaments, lipid metabolism   Neuronal death, Reactive astrogliosis   Jokic et al., 2010\
                                                                                                                                                                                     Sharp et al., 2005

                                                                                                                                                                                     

  TDP-43         Human trauma and Nerve injury animal models   DNA, RNA and protein binding                                                  Neuronal death                          Mckee et al., 2010\
                                                                                                                                                                                     Moisse et al., 2009

                                                                                                                                                                                     

  SEPT9          Humans                                        Cytoskeleton, cell division, tumorigenesis                                    Axonal degeneration                     Kuhlenbaumer et al., 2005

                                                                                                                                                                                     

  MHC2TA         Root avulsion animal models                   Major MHC class II                                                            Neuronal death                          Harnesk et al., 2008\
                                                                                                                                                                                     Piehl et al., 2007

                                                                                                                                                                                     

  Beta App       Human trauma and injury animal models         Protein cleavage, oxidative stress                                            Neurofibrillary tangles                 Li et al., 1995\
                                                                                                                                                                                     Uryu et al., 2002\
                                                                                                                                                                                     Uryu et al., 2007

                                                                                                                                                                                     

  FGF            Dominant negative animals                     Angiogenesis, wound healing, embryonic development                            Cellular death                          Eckenstein et al., 2006

                                                                                                                                                                                     

  HSP            Animal models                                 Molecular chaperones, oxidative stress, apoptosis                             Neuronal death                          Reddy et al., 2008
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The table details for each gene, the experimental context where the effect of the gene was tested and the molecular pathways through to be implicated in the specific gene-driven molecular response to trauma.

![**Schematic diagram showing the cascade of molecular changes initiated by an injury to the spinal cord, which leads to neuronal dysfunction and death**. Those genes thought to be able to modify the effect of trauma (Table 1) have the potential to alter each of the reported molecular pathways, by inhibition (red line) or by activation of a specific response (green arrow), thus changing the overall molecular profile in the injured tissue and affecting the rate of neuronal death.](1750-1326-7-6-3){#F3}

Change in lipid metabolism and in the homeostasis of lipid mediators is another route through which genes are thought to modulate the nervous tissue susceptibility to trauma, similarly to what was previously discussed for the *SOD1*gene. For example, beta amyloid is known to modulate lipid peroxidation whilst Apoe is a lipid-binding protein that is important in the redistribution of lipids among cells in the CNS and in cholesterol transport \[[@B72],[@B74],[@B78]-[@B80]\] . Mutations of the ATP-binding cassette transporter subfamily D1 *(ABCD1)*gene, which encode for defective protein transporters in the peroxisomal membrane, affect the homeostasis of saturated and unbranched very long-chain fatty acids. Traumas can precipitate X-linked adrenoleukodystrophy (X-ALD) in young males or a milder variant of this condition named adrenomyeloneuropathy (AMN) in *ABCD1*mutation carriers, a slowly progressive axonopathy in the spinal cord tracts and in the peripheral nerves \[[@B81]-[@B84]\]. In some cases, neuroimaging has shown how the pathological expression of the disease following trauma remains confined to the CNS and to the spinal cord areas more directly affected by the mechanical injury \[[@B83],[@B85]-[@B89]\].

Several of the genes mentioned above are likely to modulate tissue vulnerability to mechanical trauma through oxidative stress, an important determinant of SCI-induced secondary injury neuronal loss. X-ALD post mortem brains \[[@B90]\] and mouse model of X-ALD \[[@B91]\] show significant levels of oxidative damage. Mice deficient in Bach1, a transcriptional repressor of the heme oxygenase-1 *(Hmox1)*gene which has a cytoprotective and anti-oxidant effect, showed a better profile of functional recovery following moderate SCI and a significant smaller area of injury \[[@B92],[@B93]\]. *ABCD1*can also give rise to inflammatory-related demyelination \[[@B81]\]. Trauma-induced lipid peroxidation in mutant *App*animals is also pointing towards oxidative stress as well as a deranged lipid metabolism as important factors in the determination of susceptibility to trauma \[[@B79]\].

Variants of genes exerting control over the inflammatory response, like polymorphisms of the *Ciita (alternative symbol: Mhc2ta)*have been reported to be associated with both lower expression of MHC class II-associated genes and with an increased neurodestruction in animal models of root avulsion injury \[[@B94],[@B95]\]. *ApoE4*increases the inflammatory tone following neurotrauma with a significant surge of Il6, Tnf and nitric oxide in the injured tissue \[[@B96]\]. Heat shock proteins (HSPs) are intracellular stress-responsive molecular chaperons, which participate in the secondary injury phase by scavenging damaged proteins. Whilst universally known to provide an effective clearance of abnormal proteins, their recognized motor-cell sparing effect in SCI effect is linked to their ability to prevent chronic inflammation, once these proteins are released by acutely stressed microglial, endothelial, and ependymal cells, \[[@B97]\].

The silencing or ablation in dominant-negative animals of the fibroblast growth factor receptor (*Fgfr*), which is known to inhibit fibroblast growth factor (Fgf) signaling, does not appear to cause any overt neurological disorder. However, this genetic manipulation seems to induce a higher level of neuronal vulnerability to a stab injury to the spinal cord in mice \[[@B98]\]. Endogenous Fgf released by astrocytes and neurons after mechanical injury is thought to counteract the excitotoxic or ischemic damage by activating anti-apoptotic signals in stressed neurons \[[@B98]\].

Mannose binding lectin (*Mbl1/2*)-deficient mice have been described to show exacerbated CA3 cell death and remarkable behavioral changes after traumatic brain injury, compared to wild type mice \[[@B99]\]. Mannose binding lectin is a glycoprotein of the collectin family that plays an important role in the host\'s initial response to infection by initiating complement activation and promoting phagocytosis by leukocytes \[[@B100]\]. The septin-9 *(SEPT9)*gene has been associated to an increased susceptibility to develop a form of brachial plexus pathology as a result of different stressors including immunizations and traumas \[[@B3]\]. *SEPT9*belongs to the septin family of proteins, GTPases active on cell cycle and on cytoskeletal components, including microtubules and actin \[[@B3]\].

Conclusions: SCI and the molecular point of no return
=====================================================

The neurological impairment induced by SCI may gradually subside or, despite comprehensive rehabilitative efforts over a period of time, turn into an irreversible functional deficits. More atypical post-injury clinical pictures include localized, non-progressive as well as diffused and evolving forms of amyotrophy, neurological pictures very close to what observed in MND \[[@B101]\]. In some other cases, protracted and repetitive mechanical stress like the strenuous use of a limb due to particular occupational exposures or professional sports have been linked to the development of recurrent painful brachial plexus neuropathies, with features of muscle weakness and atrophy as well as sensory loss, similarly to what seen in hereditary neuralgic amyotrophies \[[@B3]\]. Whether permanent or progressive, the neurological consequences of trauma reflect a complex interplay of genetic and environmental factors, which condition an individual\'s susceptibility to withstand injury. This paper has embraced the body of experimental data describing genes which may potentially modulate susceptibility to trauma, in order to dissect those molecular events that may be responsible of the establishment of irreversible neurodegeneration in the post-injury phase, here defined as the \"point of no return\".

We postulate that the response of each individual to injury may operate according to a \"molecular threshold\", beyond which the response to a particular type of SCI leads to relentless tissue destruction and functional loss. The relatively few studies that have developed an experimental strategy to explore this concept have shown that the genetic determinants likely to be involved in this \"fatal switch\" modulate inflammation and oxidative stress, participate in lipid metabolism, protein cleavage and in neurofilaments homeostasis, whilst altering the balance between apoptotic and growth signals (Figure [3](#F3){ref-type="fig"}). It is likely that the contribute of the reported gene modifiers through the molecular pathways activated in injured tissue and their effect in defining the final outcome of SCI, rely on an altered profile of expression of most of the components of these molecular cascades and also to the change of their spatio-temporal regulation with regard to the time and site of injury. For example, a *SOD1*gene mutation in a pre-symptomatic rat exposed to compression SCI changes significantly the unravelling of molecular events in the first week following the trauma, resulting in a more robust inflammatory response occurring sooner after the impact. The injured tissue neurofilaments heavy chain expression does not decline significantly and the activation of genes involved in lipid metabolism does take place sooner and in a much bigger scale, compared to wild type littermates under the same experimental conditions \[[@B28]\]. The first two events mentioned above are likely to have a detrimental effect through the increased inflammatory and apoptosis-mediated cell destruction and through a surge of cytoskeletal protein aggregation undermining axonal transport, whereas the third event would likely promote cell survival. The post-injury change of homeostasis of lipid and inflammatory mediators, as well as of neurofilaments are examples of complex molecular signals involved in the modulation of irreversible neurodegeneration in different pathological contexts, particularly in ALS \[[@B102],[@B103]\]. The up-regulation of lipids in the post-injury phase is in line with what has been reported in ALS patients and in animal models of ALS, where an early derangement of mediators of lipid homeostasis is a distinctive feature of the pathology and may be part of a rescue mechanism of degenerating neurons \[[@B102]\].

The modality of mechanical force applied to the spinal cord and the level of tissue penetration account also for the different post-injury behaviour in the same *SOD1*gene mutated rat model. Compression and stabbing spinal cord injuries on the pre-symptomatic G93A-SOD1 rat model of ALS, for example, evoke completely different tissue responses at both molecular and cellular level \[[@B28],[@B57]\]. Surviving motor neurons in the G93A-SOD1 rodents subjected to compression SCI undergo significant atrophy when compared to wild type littermates, a feature not seen using penetrating injuries in the same animal model \[[@B28],[@B57]\].

Both in animal models of most neurodegenerative disorders and in real life, neurotrauma may precipitate the pathological process which is already altering the fine structure and the function of a macroscopically intact tissue. The injury may simply accelerate the course of neurodegeneration, which would have otherwise followed a different time line. Aging is clearly an important factor in this interaction, as it is an important risk factor for the development of neurodegenerative disorders and of the subtle molecular changes that pre-date the main clinical manifestations of most neurological conditions.

Understanding the molecular framework of the response to SCI in relationship to aging and to the presence of a potential underlying genetic vulnerability is an essential precondition for the development of disease-modifying treatments, of prognostic biomarkers and to monitor the response to a targeted and timely treatment strategy. A better knowledge of the molecular framework which conditions the outcome from neurotrauma is also an ideal ground for a better understanding of the wider concept of both idiopathic and genetically-induced neurodegeneration.
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